Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose pulsatile sorafenib exposure-escalation study in advanced solid tumors
NL-OMON45075Phase 1Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sorafenib in Non-hematologic malignancy, sponsored by Vrije University Medical Center. Primary endpoints: Maximum tolerated plasma exposure and Safety and tolerability. Started Nov 2015; status: active, not recruiting.
02
Drugs
sorafenib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on NL-OMON45075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45075.